Multiple Sclerosis Clinical Trial
Official title:
Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in a Natalizumab Treated Population With Active Control Assessment
The purpose of the study is to research the association between receiving Tysabri®
(natalizumab), interferon beta-1a, glatiramer acetate or not having any treatment for your
MS and how it may or may not impact certain white blood cells and other immunological
markers. This information may be useful in identifying risk factors in developing
progressive multifocal leukoencephalopathy (PML). It does appear that the risk increases
with the total number of natalizumab infusions. Patients who have not yet started a disease
modifying therapy or who have been on one other than natalizumab are needed as controls to
see how these biomarkers change.
Patients at various stages of natalizumab treatment as well as natalizumab naïve are needed
to allow for analysis of the change in potential markers over time.
Patients at various timepoints in their MS treatment or who are beginning certain MS
treatments will be consented and have blood specimens collected to allow for an
immunological comparison. The decision to treat with disease modifying therapies is made
independently from this observational study.
Primary endpoint: To further understand the delineation of lymphocyte cell adhesion marker
down regulation within a treatment naïve patient population and at various stages of
treatment.
Secondary endpoint: To understand the correlation between natalizumab pharmacodynamics,
pharmacokinetics and lymphocyte cell adhesion marker down regulation.
The results of various biomarkers and immunological testing (including CD62L, LFA-1, sCD62L,
sLFA-1, sVCAM, VLA-4 saturation, IgG4, CBC with absolute differential) will be compared
amongst the groups consented. The treatment naive group will be compared longitudinally.
;
Observational Model: Cohort
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
| Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
| Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
| Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
| Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
| Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
| Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
| Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
| Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
| Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
| Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
| Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
| Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
| Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
| Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |